Crossject SA

DIJON, I0 · CIK 0002136893 · Medtech · Public

ZENEO needle-free injection platform for delivering pharmaceutical solutions

crossject.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$10M
1 Form D · Jun 2026
4 months since last filing
Contracts
$104M
1 award · Health and Human S
#10 of 4531 in medtech
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Health and Human Services · Advanced Research And Development And Delivery Of Adult And Pediatric Midazolam Autoinjectors That Have Received Emergency Use Authorization (eua) Or Fda Approval For The Treatment Of Status Epilepticus Seizures In Adult And Pediatric Populations (2+$104,152,986
Private capital raisedForm D · SEC$10,259,936
Federal contract · USAspendingForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
7Synchron$170M$82M
8Foundation Medicine, Inc.$158M$59M
9Inbios International Inc$146M—
10Crossject SA$104M$10M
11Stratatech Corporation$98M$3.0M
12RAPISCAN LABORATORIES, INC.$68M—
13SELUX DIAGNOSTICS, INC.$63M$124M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Patrick AlexandreDirector · Executive Officer
  • Olivier LacombeExecutive Officer
  • Isabelle LiebschutzDirector · Executive Officer
  • Didier MorinExecutive Officer
  • Lionel SeltzExecutive Officer
  • Tony TiptonExecutive Officer

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.